Literature DB >> 6740079

Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine.

A B Sabin.   

Abstract

Since its first mass use in 1960, oral polio vaccine ( OPV ) has largely eliminated paralytic poliomyelitis from temperate-climate and subtropical regions of the world that have good health services and a combined total population of almost 2,000 million people. The various strategies used in these countries have been highly successful even where, as in the USA, large numbers of children received no vaccine or only a single dose of OPV . During the period of 1981-1982, only 2.8 cases per 100 million total population per year were reported in the USA. The main challenge in the present era is the economically undeveloped tropical and subtropical regions with inadequate health services that are inhabited by more than half of the world population, where recent surveys for residual paralysis due to poliomyelitis have shown that the incidence of the disease has been higher than it was in the USA and other predominantly temperate-climate countries before the vaccine era. The problem in these countries is that the majority of children receive no vaccine and that the extensive year-round dissemination of virulent polioviruses requires a different strategy of vaccination from that used in the temperate-climate countries. The special point about the annual mass vaccinations with OPV for all children younger than three, four, or five years of age-which have proven highly successful in Cuba (for the past 20 years), in Brazil (during the past three years), and recently also in Mexico-is that all the children are usually vaccinated within one or two days, which quickly breaks the chain of transmission of the virulent viruses, and the annual campaigns create and maintain the maximum number of children with resistant intestinal tracts.

Entities:  

Keywords:  Climate; Community-based Distribution; Data Analysis; Delivery Of Health Care; Demographic Factors; Demographic Impact; Developed Countries; Developing Countries; Diseases; Distributional Activities; Environment; Evaluation; Geographic Factors; Health; Health Services; Immunization; Medicine; Nonclinical Distribution; Organization And Administration; Population; Population Dynamics; Preventive Medicine; Primary Health Care; Program Activities; Programs; Research Methodology; Spatial Distribution; Vaccination--administraction and dosage; Viral Diseases--prevention and control

Mesh:

Substances:

Year:  1984        PMID: 6740079     DOI: 10.1093/clinids/6.supplement_2.s391

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

1.  Polio eradication--target 2000.

Authors:  S Gomber; K N Agarwal
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

2.  Global eradication of poliomyelitis: benefit-cost analysis.

Authors:  K J Bart; J Foulds; P Patriarca
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 3.  Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses.

Authors:  A B Sabin
Journal:  Eur J Epidemiol       Date:  1991-03       Impact factor: 8.082

4.  Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries.

Authors:  A B Sabin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22

5.  Impact of annual immunisation programme with oral polio vaccine on the prevalence of paralytic poliomyelitis.

Authors:  R Khajuria; N Datta; R Kumar; T Kaur; M K Kaushal; S Singhi; V Kumar
Journal:  Indian J Pediatr       Date:  1989 May-Jun       Impact factor: 1.967

6.  Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control.

Authors:  A B Sabin
Journal:  Eur J Epidemiol       Date:  1991-01       Impact factor: 8.082

Review 7.  Future of polio vaccines.

Authors:  Ellie Ehrenfeld; John Modlin; Konstantin Chumakov
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.